ArticleFrontiers in cardiovascular medicine2025
Global burden, temporal trends and geographic disparities of younger-onset atrial fibrillation in adults aged 30-45 years, 1990-2021: a population-based study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to estimate the global burden, temporal trends, and geographic disparities of younger-onset atrial fibrillation (AF) in adults aged 30-45 years across 204 countries from 1990 to 2021, using data from the Global Burden of Disease Study. Focusing on this under-researched age group, we aimed to characterize the epidemiology of premature AF and its implications for prevention strategies. Methods: We analyzed the global burden of younger-onset AF (30-45 years) from 204 countries using Global Burden of Disease Study 2021 data. The primary outcomes included age-standardized prevalence, mortality, disability-adjusted life years (DALYs), and average annual percentage change (AAPC). Results: From 1990 to 2021, the age-standardized prevalence of AF among young and middle-aged adults decreased slightly from 57.81 to 57.48 cases per 100,000 population, with an AAPC of 0 (95% CI -0.05 to 0.05). Age-standardized mortality rates (ASMR) increased from 0.04 to 0.05 per 100,000 population, with an AAPC of 0.17% (95% CI 0.08 to 0.26). The age-standardized DALYs rate (ASDR) rate rose from 6.98 to 7.08 per 100,000 population (AAPC 0.05%, 95% CI -0.02 to 0.11). Men exhibited higher AF-related mortality, with an AAPC of 0.3% (95% CI 0.14 to 0.47). Higher Socio-demographic Index (SDI) countries showed higher AF prevalence (e.g., 111.54 per 100,000 in Australasia) but lower mortality rates, whereas low-SDI countries had higher mortality rates (AAPC 0.49% for low-middle SDI). Regional analysis revealed the highest prevalence increase in East Asia (AAPC 0.72%). Conclusions: From 1990 to 2021, the global age-standardized prevalence and ASDR for AF in adults aged 30-45 remained stable, though ASMR slightly increased, particularly among men and in regions with lower SDI. These findings emphasize the need for targeted prevention strategies to reduce AF-related mortality in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.